Food Effect in Humans: Predicting the Risk Through In Vitro Dissolution and In Vivo Pharmacokinetic Models

AAPS Journal

Volumn 17, Issue 4, 2015, Pages 988-998

  Mathias, Neil ^a   Xu, Yan ^a   Vig, Balvinder ^a   Kestur, Umesh ^a   Saari, Amy ^a   Crison, John ^a   Desai, Divyakant ^a   Vanarase, Aditya ^a   Hussain, Munir ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

biorelevant dissolution; dog food effect model; food effect; in vitro in vivo relationship

Indexed keywords

ANIMAL EXPERIMENT; ARTICLE; BEAGLE; BIOAVAILABILITY; CONTROLLED STUDY; DISSOLUTION; FEMALE; FOOD ANALYSIS; FOOD COMPOSITION; FOOD INTAKE; FOOD QUALITY; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; NONHUMAN; PHYSICAL CHEMISTRY; RETROSPECTIVE STUDY; RISK ASSESSMENT; ANIMAL; AREA UNDER THE CURVE; BIOLOGICAL MODEL; CHEMISTRY; COMPUTER SIMULATION; DIET RESTRICTION; DOG; FOOD DRUG INTERACTION; MALE; METABOLISM; PHARMACOKINETICS; SOLUBILITY; SPECIES DIFFERENCE;

DRUG;

ANIMALS; AREA UNDER CURVE; COMPUTER SIMULATION; DOGS; FASTING; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SOLUBILITY; SPECIES SPECIFICITY;

EID: 84931573683     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-015-9759-z     Document Type: Article

References (42)

1. US Food and Drug Administration. Food-effect bioavailability and fed bioequivalence studies: guidance for industry. http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126833.pdf. 2002.
2. Fleisher D, Li C, Zhou Y, Pao LH, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clin Pharmacokinet. 1999;36:233–54.
3. Charman WN, Porter C, Methani S, Dressman JB. Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of pH and lipids. J Pharm Sci. 1997;86:269–82.
4. Kostewicz ES, Abrahamsson B, Brewster M, Brouwers J, Butler J, Carlert S, et al. In vitro models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci. 2014;57:342–66.
5. Sjögren E, Abrahamsson B, Augustijns P, Becker D, Bolger MB, Brewster M, et al. In vivo methods for drug absorption—comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. Eur J Pharm Sci. 2014;57:99–151.
6. Sugano K, Kataoka M, Mathews C, Yamashita S. Prediction of food effect by bile micelles on oral drug absorption considering free fraction in the intestinal fluid. Eur J Pharm Sci. 2010;40:118–24.
7. Gu CH, Li H, Levons J, Lentz K, Gandhi RB, Raghavan K, et al. Predicting effect of food on the extent of drug absorption based on physicochemical properties. Pharm Res. 2007;24:1118–30.
8. Singh BN. A quantitative approach to probe the dependence and correlation of food-effect with aqueous solubility, dose/solubility ratio and partition coefficient (Log P) for orally active drugs administered as immediate release formulations. Drug Dev Res. 2005;65:55–75.
9. Parrott N, Lukava V, Fraczkiewicz G, Bolger MB. Predicting pharmacokinetics of drug using physiologically based modeling: application to food effects. AAPS J. 2009;11:45–53.
10. Heimbach T, Binfeng X, Liu T, He H. Case studies for practical food effect assessment across BCS/BDDCS Class compounds using in silico, in vitro and preclinical in vivo data. AAPS J. 2012;15:143–58.
11. Kostewicz ES, Aarons L, Bergstrand M, Bolger MB, Galetin A, Hatley O, et al. PBPK models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci. 2014;57:300–51.
12. Dressman JB, Reppas C. In vitro-in vivo correlation for lipophilic, poorly soluble drugs. Eur J Pharm Sci. 2000;11:S73–80.
13. Katoaka M, Itsubata S, Masaoka Y, Sakuma S, Yamashita S. In vitro dissolution/permeability system to predict the oral absorption of poorly water soluble drugs: effect of food and dose strength on it. Biol Pharm Bull. 2011;34:401–7.
14. Lentz K, Quitko M, Morgan DG, Grace JE, Gleason C, Marathe PH. Development and validation of a preclinical food effect model. J Pharm Sci. 2007;96:459–72.
15. Zane P, Guo Z, MacGerorge D, Vicat P, Ollier C. Use of the pentagastrin dog model to explore the food effects on formulations in early drug development. Eur J Pharm Sci. 2014;57:207–13.
16. Balimane P, Han YH, Chong S. Current industrial practices in assessing permeability and P-glycoprotein interactions. AAPS J. 2006;8:E1–13.
17. Lennernas H. Human jejunal effective permeability and its correlation with preclinical drug absorption models. J Pharm Pharmacol. 1997;49:627–38.
18. Benet LZ, Brocatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J. 2011;13:519–47.
19. Ku S. Use of the biopharmaceutical classification system in early drug development. AAPS J. 2008;10:208–12.
20. Galia E, Nicolaides E, Hörter D, Löbenberg R, Reppas C, Dressman JB. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res. 1998;15:698–705.
21. Sagawa K, Fasheng LL, Liese R, Sutton S. Fed and fasted gastric pH and gastric residence time in conscious beagle dogs. J Pharm Sci. 2009;98:2494–500.
22. Dressman JB. Comparison of canine and human gastrointestinal physiologies. Pharm Res. 1986;3:123–31.
23. Braganza JM, Herman K, Hine P, Kay G. The effect of pentagastrin on peptic secretion in man. J Physiol. 1979;289:9–16.
24. Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet. 1999;37:213–55.
25. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Phar Res. 2005;22:11–23.
26. Lecaillon JB, Godbillon J, Campestrini J, Naquira C, Miranda L, Pacheco R, et al. Effect of food on the bioavailability of triclabendazole in patients with fascioliasis. Br J Clin Pharmacol. 1998;45:601–4.
27. Doak AK, Wille H, Prusiner SB, Shoichet BK. Colloidal formation by drugs in simulated intestinal fluid. J Med Chem. 2010;53:4259–65.
28. Shono Y, Jantratid E, Dressman JB. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak base in the fasted state: case example nelfinavir. Eur J Pharm Sci. 2011;79:349–56.
29. Cvijic S, Parojcic J, Langguth P. Viscosity-mediated negative food-effect on oral absorption of poorly-permeable drugs with an absorption window in the proximal intestine: In vitro experimental simulation and computational verification. Eu J Pharm Sci. 2014. doi:10.1016/j.ejps.2014.04.008.
30. Shono Y, Jantratid E, Janssen N, Kesisoglou F, Mao Y, Vertzoni M, et al. Prediction of food-effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur J Pharm Biopharm. 2009;73:107–14.
31. Bevernage J, Brouwers J, Clarysse S, Vertzoni M, Tack J, Annaert P, et al. Drug supersaturation in simulated and human intestinal fluids representing different nutritional states. J Pharm Sci. 2010;99:4525–34.
32. Lui CY, Amidon GL, Berardi RR, Fleisher D, Yongberg C, Dressman JB. Comparison of gastrointestinal pH in dogs and humans—implications on the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci. 1986;75:271–4.
33. Sutton SC. Companion animal physiology and dosage form performance. Adv Drug Del Rev. 2004;56:1383–98.
34. Lentz KA. Current methods for predicting human food effect. AAPS J. 2008;10:282–8.
35. Gao ZH, Hussain MA, Motheram R, Gray DB, Benedeck IH, Fiske WD, et al. Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug. J Pharm Sci. 2007;96:2970–7.
36. Mathias NR, Crison J. The use of modeling tools to drive efficient oral product design. AAPS J. 2012;14:591–600.
37. Kawai Y, Fujii K, Tabata F, Ito J, Metsugi Y, Kameda A, et al. Profiling and trend analysis of food effects on the oral absorption considering micelle interaction and solubilization by bile micelles. Drug Metab Pharmacokinet. 2011;26:180–91.
38. Pandey P, Hamey R, Bindra DS, Huang Z, Mathias NR, Eley T, et al. From bench to humans: formulation development of a poorly water soluble drug to mitigate food effect AAPS Pharm. Sci Tech. 2014;15:407–16.
39. Daneshmend TK, Warnock DW, Ene MD, Johnson EM, Potten MR, Richardson MD, et al. Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother. 1984;25:1–3.
40. US Food and Drug Administration. Ribavirin approval package label. 2004.
41. US Food and Drug Administration. Danazol approval package review. 1996.
42. US Food and Drug Administration. Celebrex approval package label. 1998.